Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed May 15, 2024 · 10-Q · 45 days after period end · 0001558370-24-008318
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$114.29M | -$6.65M | -$19.70M | -$13.11M |
| EPS Diluted | -$8.01 | -$0.52 | -$0.09 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end
